Uterine artery embolization versus dienogest for symptomatic adenomyosis: A randomized controlled trial of short-term efficacy
RCT
OA: closed
CC0
⤵ 1 in-corpus citation
AI-generated summary
This trial found that uterine artery embolization was more effective than dienogest at resolving pain and bleeding symptoms and reducing adenomyosis lesion size at six months.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
RATIONALE AND OBJECTIVES: Adenomyosis significantly impairs quality of life, yet optimal uterine-sparing management remains uncertain. While both uterine artery embolization (UAE) and dienogest show promise, no direct comparison exists. This study compared their 6-month efficacy in treating symptomatic adenomyosis.
PATIENTS AND METHODS: This prospective, single-center, randomized controlled trial enrolled 60 patients with MRI-confirmed adenomyosis desiring uterine preservation between January and July 2025, randomly assigned (1:1) to UAE (n = 30) or 2 mg/day dienogest (n = 30). Co-primary outcomes were complete resolution of chronic pelvic pain and heavy menstrual bleeding at 6 months. Secondary outcomes included visual analog scale (VAS) dysmenorrhea scores, Uterine Fibroid Symptom and Quality of Life (UFS-QoL) symptom severity and health-related quality of life (HRQOL) scores, hemoglobin levels, junctional zone thickness, and uterine volume measured at baseline, 3 months, and 6 months.
RESULTS: UAE achieved higher complete resolution rates for chronic pelvic pain (93.3% vs. 66.7%; p = 0.010; relative risk [RR] = 1.40) and heavy menstrual bleeding (90.0% vs. 56.7%; p = 0.004; RR = 1.59), with composite success in 86.7% versus 50.0% (RR = 1.73; number needed to treat = 3). At 6 months, UAE was associated with significantly better outcomes for VAS dysmenorrhea (1.27 ± 1.23 vs. 2.10 ± 1.25; p = 0.016), symptom severity scores (31.48 ± 9.78 vs. 45.36 ± 9.55; p < 0.001), HRQOL scores (66.25 ± 7.35 vs. 50.82 ± 10.11; p < 0.001), hemoglobin levels (10.55 ± 1.49 vs. 10.19 ± 1.55 g/dL; p = 0.010), junctional zone reduction (33.5% vs. 14.0%; p = 0.005), and uterine volume reduction (17.6% vs. 7.3%; p = 0.006).
CONCLUSION: At 6 months, UAE achieved better symptom relief and anatomical outcomes than dienogest, supporting UAE as an effective uterine-sparing therapy for symptomatic adenomyosis.
My notes (saved in your browser only)
Outcome instruments
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (27)
- Adenomyosis-A Call for Awareness, Early Detection, and Effective Treatment Strategies: A Narrative Review via openalex
- Adenomyosis and Abnormal Uterine Bleeding: Review of the Evidence via openalex
- Adenomyosis: a systematic review of medical treatment via openalex
- Clinical Efficacy of Dienogest and Levonorgestrel-Releasing Intrauterine System in the Treatment of Adenomyosis via openalex
- Efficacy, Adverse Events, and Challenges of Dienogest in the Management of Symptomatic Adenomyosis: A Comparison with Different Hormonal Treatments via openalex
- Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- Expert Consensus on the Management of Adenomyosis: A Modified Delphi Method Approach by the Taiwan Endometriosis Society via openalex
- Guideline No. 437: Diagnosis and Management of Adenomyosis via openalex
- Long-term results of uterine artery embolization for symptomatic adenomyosis via openalex
- Management of uterine adenomyosis: current trends and uterine artery embolization as a potential alternative to hysterectomy via openalex
- Medical treatment for adenomyosis: long term use of progestins via openalex
- MRI of adenomyosis: changes with uterine artery embolization via openalex
- Role of transvaginal sonography and magnetic resonance imaging in the diagnosis of uterine adenomyosis via openalex
- Study of dienogest clinical efficacy in the treatment of adenomyosis via openalex
- The Present and the Future of Medical Therapies for Adenomyosis: A Narrative Review via openalex
- The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis via openalex
- Uterine Artery Embolization for Adenomyosis via openalex
- Uterine Artery Embolization for Symptomatic Adenomyosis: 7-Year Clinical Follow-up Using UFS-Qol Questionnaire via openalex
- Uterine Artery Embolization for the Treatment of Adenomyosis: A Systematic Review and Meta-Analysis via openalex
- Uterine Artery Embolization with Small-Sized Particles for the Treatment of Symptomatic Adenomyosis: A 42-Month Clinical Follow-Up via openalex
- W4402170422 via openalex
- W2101417341 via openalex
- W2739010978 via openalex
- W4322496040 via openalex
- W4328135802 via openalex
- W4240032299 via openalex
- W4400781868 via openalex
Cited by (1)
SciLite annotations
chemicals 4
dienogest
dienogest
dienogest
dienogest
Source provenance
- europepmc
- last seen: 2026-10-20T06:13:28.455750+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-10-20T06:08:05.896256+00:00
- scilite
- last seen: 2026-06-28T09:31:30.222730+00:00
- unpaywall
- last seen: 2026-10-20T06:27:24.728081+00:00
License: CC0
· commercial use OK